Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombin abnormalities and perinatal management.

Takao Kobayashi1

  • 1Shinshu University School of Health Sciences, Department of Family and Child Nursing, and Midwifery, 3-1-1 Asahi, Matsumoto City, Nagano Prefecture, 390-8621 Japan. tkoba@shinshu-u.ac.jp

Current Drug Targets
|July 20, 2005
PubMed
Summary

Antithrombin deficiency, a hereditary or acquired condition, increases thrombotic risk, especially during pregnancy. Treatment involves anticoagulants, and AT concentrates may be needed for severe cases or preeclampsia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantum Computing Calculations of Protein-Ligand Binding Energies Using Decomposition Methods on Simulated and Real Quantum Hardware.

Journal of chemical information and modeling·2026
Same author

Echocardiographic diagnosis of pulmonary thromboembolism in a preterm infant presenting with congenital chylothorax.

Pediatrics and neonatology·2026
Same author

Randomized Study of Antithrombin in Early-Onset Preeclampsia: KOUNO-TORI Study.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Group 2 innate lymphoid cells program pulmonary adaptive immunity via granulocyte-macrophage colony-stimulating factor.

The Journal of allergy and clinical immunology·2026
Same author

Impact of estetrol and drospirenone combination therapy on alleviation of the pelvic pain of endometriosis: a randomized control trial.

F&S reports·2026
Same author

Post Hoc Analysis of a Previous Study of Estetrol 15 mg/Drospirenone 3 mg Combination for Dysmenorrhea and Uterine Bleeding in Adenomyosis Patients.

Reproductive medicine and biology·2026

Area of Science:

  • Hematology
  • Obstetrics
  • Genetics

Background:

  • Antithrombin (AT) is a key regulator of coagulation, inhibiting proteases like Factor Xa and thrombin.
  • Hereditary AT deficiency presents as quantitative (Type I) or qualitative (Type II) defects.
  • Acquired AT deficiencies arise from impaired synthesis, consumption, or urinary loss.

Purpose of the Study:

  • To review the role of Antithrombin deficiency in thrombophilia.
  • To discuss the implications of AT deficiency in pregnancy and preeclampsia.
  • To outline current and potential treatment strategies.

Main Methods:

  • Literature review of Antithrombin deficiency.
  • Analysis of thrombotic risks associated with AT deficiency.
  • Examination of treatment modalities for AT deficiency.

Related Experiment Videos

Main Results:

  • AT deficiency significantly elevates maternal thromboembolism and fetal loss risks.
  • Heparin resistance can occur in severe AT deficiency, necessitating higher doses or AT concentrates.
  • Acquired AT deficiency is common in preeclampsia, with AT concentrates potentially improving outcomes.

Conclusions:

  • Antithrombin deficiency poses substantial risks during pregnancy, including thromboembolism and fetal loss.
  • Management requires careful antithrombotic therapy, with potential need for AT concentrates.
  • Further research into AT concentrate use in preeclampsia is warranted.